Publications
- Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma2013 | First Faculty of Medicine
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Standardized 18F-FDG PET/CT in patients with myeloma: joint recommendation of Czech Myeloma Group and Czech Society of Nuclear Medicine2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Standardization of PET/CT in patients with multiple myeloma – Joint recommendation of The Czech Myeloma Group and The Czech Society of Nuclear Medicine2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Diagnostika a léčba mnohočetného myelomu 2023. Doporučení České myelomové skupiny, Slovenské myelómové skupiny a Myelomové sekce České hematologické společnosti pro diagnostiku a léčbu mnohočetného myelomu2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma2023 | First Faculty of Medicine
Loading network view...